News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Mynet Finans Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
MMCAP International Inc. SPC and MM Asset Management Inc. have disclosed a 9.6% beneficial stake in Polyrizon Ltd. (PLRZ), owning 199,470 ordinary shares. This information was reported in an amended Schedule 13G filing, indicating shared voting and dispositive power over these shares. The filing …
A group of related investors, led by Xenia Venture Capital Limited, has filed an amended Schedule 13G/A for PolyPid Ltd. (PYPD), disclosing a beneficial ownership of up to 13.4% of the company's Ordinary Shares. The complex ownership structure involves Rodney Hodges, Geneva Holding Company …
HC Wainwright has lowered its FY2029 EPS estimate for PolyPid (NASDAQ:PYPD) to $0.75 from $0.80, while maintaining a "Buy" rating and a $13 price target. The firm also projected FY2030 EPS of $1.57. This adjustment follows PolyPid's recent quarterly earnings, where the company reported …
Oncolytics Biotech (NASDAQ:ONCY) reported a quarterly loss of $0.08 per share, missing analysts' consensus estimate of a $0.05 loss by $0.03. Despite the earnings miss, the stock rose 0.5% to $0.82, and institutional investors have been increasing their holdings. Analysts currently rate the stock …
PolyPid Ltd. reported an operating loss of $15.6 million and a net loss of $15.6 million for the first half of 2026, with cash and equivalents at $6.8 million, raising substantial doubt about its ability to continue as a going concern. Despite securing a …
Oncolytics Biotech Inc. (ONCY) reported a widened net loss of $9.4 million in Q2 2026, attributed to rising R&D and G&A expenses due to clinical trial expansion and increased stock-based compensation. While current cash is sufficient for near-term milestones, the company will require additional …
PolyPid Ltd. reported a narrower-than-expected loss of $0.35 per share for Q2 2026, beating analyst estimates by 10.3%. The biopharmaceutical company posted a net loss of $7.8M as it advances its PLEX platform for targeted drug delivery. Analyst consensus remains bullish, with 7 buy …
PolyPid (NASDAQ:PYPD) announced quarterly earnings of $(0.35) per share, surpassing analyst estimates by $0.03. Key developments include the FDA's priority review acceptance for D-PLEX100, a commercialization agreement with Azurity valued at $30 million upfront plus potential additional milestones, and an expected funding runway into …
Key Points Interested in PolyPid Ltd.? Here are five stocks we like better. FDA review advances: PolyPid's NDA for D-PLEX100 was accepted on July 27, 2026, with priority review and a Nov. 28 PDUFA target date. The company is preparing for a pre-approval manufacturing …
PolyPid Ltd. reported a narrowed Q2 2026 loss of $0.35 per share, exceeding analyst expectations, and highlighted significant progress with its Azurity Pharmaceuticals partnership and FDA priority review for D-PLEX100. Despite these positive developments, the stock fell 5.92% in premarket trading. The company anticipates …
PolyPid reported its Q2 2026 financial results, highlighting the FDA's acceptance of its D-PLEX100 NDA with Priority Review and a PDUFA goal date of November 28, 2026. The company also announced a commercialization agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, …
PolyPid Ltd. announced that the FDA granted Priority Review for its D-PLEX100 New Drug Application, setting a PDUFA goal date of November 28, 2026. Concurrently, PolyPid entered into an exclusive commercialization partnership with Azurity Pharmaceuticals for the U.S. and Canada, securing $30 million in …
Search by ticker symbol or company name and select a result to open its chart.